Indications

Browse indications

Filter by therapy area or team. Click an indication to see the reports available by report type and market.

Therapy area
For
Oncology

NSCLC

US · In-Market
Competitive IntelligenceDisease LandscapePatient Flow ModelPayer & HTAField-Force StrategyLaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Patient Flow ModelOpen →Payer & HTAOpen →Field-Force StrategyOpen →Launch ReadinessOpen →Indication overview→
Metabolic

MASH

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTAMarket Sizing ModelLaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Market Sizing ModelOpen →Launch ReadinessOpen →Indication overview→
Rare Disease

PNH

US · GCC · UK · FR · DE · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessPricing Strategy ModelPatient Flow ModelKOL MappingMarket Sizing ModelHTA Strategy Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Payer & HTAOpen →Payer & HTAOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Launch ReadinessOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →KOL MappingOpen →KOL MappingOpen →KOL MappingOpen →Launch ReadinessOpen →Competitive IntelligenceOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Launch ReadinessOpen →HTA Strategy ModelOpen →Disease LandscapeOpen →Disease LandscapeOpen →Payer & HTAOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Disease LandscapeOpen →Market Sizing ModelOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Market Sizing ModelOpen →Disease LandscapeOpen →Pricing Strategy ModelOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Indication overview→
Immunology

Atopic Dermatitis

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Indication overview→
Metabolic

Type 2 Diabetes

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessPricing Strategy ModelMarket Sizing Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Indication overview→
Metabolic

Obesity

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTAPricing Strategy ModelLaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Pricing Strategy ModelOpen →Launch ReadinessOpen →Indication overview→
Neurology

Alzheimer's Disease

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Indication overview→
Rare Disease

IgA Nephropathy

US · GCC · UK · In-Market
Competitive IntelligencePayer & HTADisease LandscapeLaunch ReadinessKOL MappingMarket Sizing ModelPatient Flow ModelPricing Strategy ModelHTA Strategy Model
Competitive IntelligenceOpen →Payer & HTAOpen →Disease LandscapeOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Launch ReadinessOpen →KOL MappingOpen →KOL MappingOpen →Launch ReadinessOpen →Payer & HTAOpen →Disease LandscapeOpen →Payer & HTAOpen →Market Sizing ModelOpen →Disease LandscapeOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Pricing Strategy ModelOpen →HTA Strategy ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Competitive IntelligenceOpen →Indication overview→
Rare Disease

Hereditary Angioedema

US · GCC · UK · In-Market
Competitive IntelligenceDisease LandscapePayer & HTAPricing Strategy ModelMarket Sizing ModelPatient Flow ModelKOL MappingLaunch ReadinessHTA Strategy Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Patient Flow ModelOpen →Competitive IntelligenceOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →KOL MappingOpen →KOL MappingOpen →Disease LandscapeOpen →Disease LandscapeOpen →Launch ReadinessOpen →Payer & HTAOpen →HTA Strategy ModelOpen →Payer & HTAOpen →Launch ReadinessOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Indication overview→
Rare Disease

ATTR Amyloidosis

US · UK · GCC · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessPatient Flow ModelMarket Sizing ModelKOL MappingHTA Strategy ModelPricing Strategy Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Payer & HTAOpen →Disease LandscapeOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Market Sizing ModelOpen →KOL MappingOpen →KOL MappingOpen →Launch ReadinessOpen →Launch ReadinessOpen →HTA Strategy ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Payer & HTAOpen →Market Sizing ModelOpen →Disease LandscapeOpen →Market Sizing ModelOpen →Indication overview→
Rare Disease

Myasthenia Gravis

US · UK · GCC · In-Market
Competitive IntelligencePayer & HTADisease LandscapeMarket Sizing ModelPatient Flow ModelKOL MappingLaunch ReadinessHTA Strategy ModelPricing Strategy Model
Competitive IntelligenceOpen →Payer & HTAOpen →Disease LandscapeOpen →Market Sizing ModelOpen →Disease LandscapeOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Competitive IntelligenceOpen →Patient Flow ModelOpen →KOL MappingOpen →KOL MappingOpen →Launch ReadinessOpen →HTA Strategy ModelOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Payer & HTAOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Competitive IntelligenceOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Indication overview→
Rare Disease

Dravet Syndrome

US · GCC · UK · In-Market
Disease LandscapePayer & HTACompetitive IntelligenceLaunch ReadinessPatient Flow ModelMarket Sizing ModelKOL MappingHTA Strategy ModelPricing Strategy Model
Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Competitive IntelligenceOpen →Payer & HTAOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Disease LandscapeOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →KOL MappingOpen →Payer & HTAOpen →HTA Strategy ModelOpen →Launch ReadinessOpen →Disease LandscapeOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →KOL MappingOpen →Indication overview→
Rare Disease

Pompe Disease

US · UK · GCC · In-Market
Competitive IntelligenceDisease LandscapePayer & HTAMarket Sizing ModelPatient Flow ModelKOL MappingHTA Strategy ModelLaunch ReadinessPricing Strategy Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Disease LandscapeOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Competitive IntelligenceOpen →Competitive IntelligenceOpen →Payer & HTAOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →KOL MappingOpen →KOL MappingOpen →Disease LandscapeOpen →HTA Strategy ModelOpen →Payer & HTAOpen →Launch ReadinessOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Launch ReadinessOpen →Indication overview→
Rare Disease

Fabry Disease

US · UK · GCC · In-Market
Competitive IntelligencePayer & HTADisease LandscapePatient Flow ModelKOL MappingLaunch ReadinessPricing Strategy ModelHTA Strategy ModelMarket Sizing Model
Competitive IntelligenceOpen →Payer & HTAOpen →Disease LandscapeOpen →Competitive IntelligenceOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Payer & HTAOpen →KOL MappingOpen →KOL MappingOpen →Launch ReadinessOpen →Payer & HTAOpen →Disease LandscapeOpen →Pricing Strategy ModelOpen →HTA Strategy ModelOpen →Disease LandscapeOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Competitive IntelligenceOpen →Market Sizing ModelOpen →Launch ReadinessOpen →Indication overview→
Rare Disease

Spinal Muscular Atrophy

US · GCC · UK · In-Market
Disease LandscapePayer & HTACompetitive IntelligencePricing Strategy ModelMarket Sizing ModelPatient Flow ModelKOL MappingLaunch ReadinessHTA Strategy Model
Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Payer & HTAOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →Patient Flow ModelOpen →KOL MappingOpen →KOL MappingOpen →Disease LandscapeOpen →Payer & HTAOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →Competitive IntelligenceOpen →Launch ReadinessOpen →HTA Strategy ModelOpen →Launch ReadinessOpen →Disease LandscapeOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Indication overview→
Rare Disease

Sickle Cell Disease

US · GCC · UK · In-Market
Competitive IntelligencePayer & HTADisease LandscapeMarket Sizing ModelLaunch ReadinessPatient Flow ModelKOL MappingHTA Strategy ModelPricing Strategy Model
Competitive IntelligenceOpen →Payer & HTAOpen →Disease LandscapeOpen →Market Sizing ModelOpen →Payer & HTAOpen →Launch ReadinessOpen →Competitive IntelligenceOpen →Patient Flow ModelOpen →Competitive IntelligenceOpen →Patient Flow ModelOpen →KOL MappingOpen →KOL MappingOpen →Payer & HTAOpen →Patient Flow ModelOpen →Disease LandscapeOpen →Disease LandscapeOpen →HTA Strategy ModelOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Market Sizing ModelOpen →Indication overview→
Rare Disease

Gaucher Disease

US · In-Market
Payer & HTACompetitive IntelligenceDisease LandscapePricing Strategy ModelMarket Sizing ModelLaunch Readiness
Payer & HTAOpen →Competitive IntelligenceOpen →Disease LandscapeOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Launch ReadinessOpen →Indication overview→
Rare Disease

Cold Agglutinin Disease

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessPricing Strategy ModelMarket Sizing Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Market Sizing ModelOpen →Indication overview→
Oncology

Breast Cancer HR+/HER2-

US · UK · In-Market
Competitive IntelligenceDisease LandscapePayer & HTAKOL MappingHTA Strategy ModelMarket Sizing ModelLaunch ReadinessPricing Strategy ModelPatient Flow Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →KOL MappingOpen →HTA Strategy ModelOpen →Market Sizing ModelOpen →Launch ReadinessOpen →KOL MappingOpen →Pricing Strategy ModelOpen →Patient Flow ModelOpen →Indication overview→
Pulmonology

COPD

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch Readiness
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Indication overview→
Immunology

Plaque Psoriasis

US · In-Market
Competitive IntelligenceDisease LandscapePayer & HTALaunch ReadinessPricing Strategy Model
Competitive IntelligenceOpen →Disease LandscapeOpen →Payer & HTAOpen →Launch ReadinessOpen →Pricing Strategy ModelOpen →Indication overview→

Don't see your indication?

Commission any indication, comparator set and market — delivered in 72 hours.

Commission a Report